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BACKGROUND AND PURPOSE
Mucociliary malfunction occurs in chronic obstructive pulmonary disease (COPD) and compromised functions of ciliated
bronchial epithelial cells may contribute to this. Cigarette smoke, a major risk factor for COPD, impairs ciliary beat frequency
(CBF). cAMP augments CBF. This in vitro study addressed, in differentiated, primary human bronchial epithelial cells, whether
roflumilast N-oxide, a PDE4 inhibitor, (i) augments CBF; (ii) prevents the reduction in CBF induced by cigarette smoke extract
(CSE); and (iii) protects against the loss of the ciliated phenotype following long-term CSE exposure.
EXPERIMENTAL APPROACH
Air-liquid interface cultured human bronchial epithelial cells were incubated with roflumilast N-oxide and exposed to CSE. CBF
was assessed by digital high speed video microscopy (DHSV). Ciliated cells were characterized by b-tubulin IV staining and
analyses of Foxj1 and Dnai2 mRNA and protein (real-time quantitative PCR, Western blotting).
KEY RESULTS
Roflumilast N-oxide concentration-dependently triggered a rapid and persistent increase in CBF and reversed the decrease in
CBF following CSE. Long-term incubation of bronchial epithelial cells with CSE resulted in a loss in ciliated cells associated
with reduced expression of the ciliated cell markers Foxj1 and Dnai2. The PDE4 inhibitor prevented this loss in the ciliated cell
phenotype and the compromised Foxj1 and Dnai2 expression. The enhanced release of IL-13 following CSE, a cytokine that
diminishes the proportion of ciliated cells and in parallel, reduces Foxj1 and Dnai2, was reversed by roflumilast N-oxide.
CONCLUSION AND IMPLICATIONS
Roflumilast N-oxide protected differentiated human bronchial epithelial cells from reduced CBF and loss of ciliated cells
following CSE.
Abbreviations
CBF, ciliary beat frequency; COPD, chronic obstructive pulmonary disease; CSE, cigarette smoke extract; DHSV, digital
high speed video imaging technique; Dnai2, axonemal dynein intermediate polypeptide 2; DUOX, dual oxidase; Foxj1,
forkhead transcription factor 1; NAC, N-acetyl cysteine; NOX, NADPH oxidase; ROS, reactive oxygen species
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Introduction
Mucociliary clearance is a major host defence mechanism of
the lungs and is governed by the bronchial epithelium. The
coordinated secretion of airway mucus from goblet cells
along with synchronized ciliary beating and maintenance of
the periciliary lining fluid at an optimal height by ciliated
epithelium provides an efficient defence from inhaled
noxious particles and pathogens (Wanner et al., 1996).
The frequency of ciliary beating is controlled by numer-
ous factors such as temperature, pH, noxious particles and
pathogens, a number of endogenous mediators present in the
periciliary lining fluid (e.g. ATP, adenosine, nitric oxide),
stress and exercise or by therapeutic interventions (Olseni
and Wollmer, 1990; Salathe, 2007). Most of these factors
modify cellular levels of Ca2+, cAMP or cGMP. Indeed, activa-
tion of cAMP-dependent PKA enhances ciliary beat frequency
(CBF) secondary to a specific phosphorylation of dynein light
chains (Salathe, 2007).
Tobacco smoking is acknowledged as the major risk factor
of chronic obstructive pulmonary disease (COPD). By
anatomy, bronchial epithelial cells are the primary target of
tobacco smoke. As a corollary, cigarette smoke (CS) was
shown to impair CBF in vitro, in vivo and in patients (Bal-
lenger, 1960; Elliott et al., 2007; Simet et al., 2010), and a role
of an activated PKCe (Salathe et al., 1993; Elliott et al., 2007;
Salathe, 2007; Simet et al., 2010) was discussed in this
context. Such a compromised CBF adds to mucus hypersecre-
tion, impaired functioning of Cl--secreting channels, loss of
ciliated epithelial cells secondary to tobacco smoke altogether
resulting in malfunction of the mucociliary apparatus that is
considered to be a major disease mechanism in COPD (Sisson
et al., 1994; Gensch et al., 2004; Tamashiro et al., 2009).
CBF is augmented by cAMP and one option to increase
cellular cAMP is to prevent its degradation through inhibition
of cyclic nucleotide hydrolysing PDEs. The PDE superfamily
comprises 11 families (PDE1-11). Among these, the cAMP
selectively hydrolysing PDE4 has attracted much interest as a
therapeutic target in respiratory ailments such as COPD. The
PDE4 family is composed of four subtypes (PDEA-D) encoded
by different genes that by alternative splicing are expressed as
multiple variants with sequence diversity in their N-terminal
domains (Conti et al., 2003; Houslay et al., 2005). PDE4 was
found and shown to be of functional relevance in virtually all
cells related to COPD. Among them are airway epithelial cells
where selective PDE4 inhibitors (i) suppress EGF-induced pro-
duction of the MUC5AC mucus protein (Mata et al., 2005); (ii)
enhance activity of the cystic fibrosis transmembrane con-
ductance regulator Cl--secreting channel (Barnes et al., 2005);
and (iii) increase CBF (Cervin and Lindgren, 1998; Wohlsen
et al., 2010) that altogether may integrate into an improved
mucociliary clearance. Specifically, the PDE4 inhibitor rol-
ipram was reported to augment CBF of epithelial cells from
rabbit maxillary sinus and trachea (Cervin and Lindgren,
1998) and in rat precision cut lung slices (Wohlsen et al.,
2010). In the latter protocol, the PDE4 inhibitor roflumilast
was more potent than rolipram at increasing CBF.
The first PDE4 inhibitor roflumilast is now available for
the treatment of severe COPD. Indeed, in large clinical trials
(over up to 1 year), roflumilast improved lung function and
reduced the rate of acute exacerbations in severe COPD (Cal-
verley et al., 2009; Fabbri et al., 2009). The clinical benefit of
roflumilast is considered to emanate primarily from its anti-
inflammatory effects, although results from cellular and
animal studies indicate that the PDE4 inhibitor also has the
potential to curb lung architectural remodelling, mucociliary
malfunction and the burden of oxidative stress that are often
associated with COPD (Hatzelmann et al., 2010).
The current study was mainly dedicated to explore the
effects of the PDE4 inhibitor roflumilast N-oxide on ciliated
human bronchial epithelial cells (in an air-liquid interface
culture) compromised by exposure to cigarette smoke extracts
(CSEs) in vitro. Roflumilast N-oxide is the active metabolite of
roflumilast that largely accounts for its clinical efficacy (Hat-
zelmann and Schudt, 2001; Bethke et al., 2007; Hatzelmann
et al., 2010). The culture of bronchial epithelial cells on
porous membranes in an air-liquid interface protocol allows
formation of a pseudostratified epithelium comprising cili-
ated cells, mucus producing cells and basal cells that is widely
accepted as an appropriate model to reflect differentiated
bronchial epithelium in situ.
Methods
Isolation of bronchial epithelial cells and
air-liquid interface culture
Primary human bronchial epithelial cells were isolated and
cultured from human lung tissue of patients undergoing
surgery for lung cancer (approval of the local ethics commit-
tee and informed consent was obtained). Small pieces of
bronchi were excised from microscopically normal lung
areas, carefully dissected free from lung parenchyma and
plated on collagen-coated culture dishes [10 mg·cm-2 rat type
I collagen (Sigma) in bronchial epithelial growth medium
(BEGM, comprising bronchial epithelial basal medium sup-
plemented with bovine pituitary extract 52 mg·mL-1, hydro-
cortisone 0.5 mg·mL-1, human recombinant EGF 25 ng·mL-1,
adrenaline 0.5 mg·mL-1, transferrin 10 mg·mL-1, insulin
5 mg·mL-1, retinoic acid 50 nM, triiodo-L-thyronine
6.5 ng·mL-1, gentamycin 40 mg·mL-1, amphotericin B
50 ng·mL-1, bovine serum albumin 1.5 mg·mL-1)]. Small
bronchi were orientated with the epithelial layer to be in
contact with the culture plate. After a period of approxi-
mately 2 weeks, bronchial epithelial cells were observed
around bronchi. The identity of the monolayer as bronchial
epithelial cells was affirmed by morphological criteria and
immunofluorescence for cytokeratin 5. At about 75% conflu-
ency, bronchi were removed and cells were trypsinized and
subpassaged on polyester Transwell inserts (Millipore, Bill-
erica, MA, USA) at 82 500 cells per insert. Cells were left for 7
days submerged in BEGM/Dulbecco’s modified Eagle’s
minimal essential medium 1:1. From day 7, the air-liquid
interface culture was initiated by removing the medium from
the upper well leaving the apical surface of the cells exposed
to air and changing the final EGF concentration to
0.5 ng·mL-1 (differentiation medium). In general, air-liquid
interface cultures were pursued until about 80–90% of cells
were ciliated by microscopic inspection (about 3–4 weeks
after initiation) before experiments were commenced. Cells
were maintained at 37°C with 5% CO2 and medium changed
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every other day. At this stage, a pseudostratified bronchial
epithelium comprising basal cells, ciliated cells and goblet
cells was obtained and considered as ‘differentiated’.
Preparation of CSE and incubations
CSE solutions were prepared as previously described (Ortiz
et al., 2010). Briefly, the smoke of a research cigarette (2R4F,
from Tobacco Health Research, University of Kentucky,
Orlando, KY, USA) was bubbled into a flask containing 25 mL
of pre-warmed (37°C) differentiation medium using a respi-
ratory pump model (Harvard Apparatus Rodent Respirator
680, Harvard Apparatus, Holliston, MA, USA) that operates
through a puffing mechanism corresponding to the human
smoking pattern (three puffs min-1; 35 mL per each puff of 2 s
duration with a volume of 0.5 cm above the filter). The CS
solution was then drawn into a syringe through a 0.22 mm
pore size filter to remove particles and the tar phase and to
obtain a sterile solution (Corning, NY, USA). The resulting
solution was defined as CSE at 100% and used in the different
experiments within 30 min of preparation following
appropriate dilution as indicated. CSE at 10% reportedly cor-
responds to an exposure associated with smoking of approxi-
mately two packs per day (Su et al., 1998). Cytotoxicity
possibly emanating from CSE was analysed by exposing dif-
ferentiated bronchial epithelial cells to 10% CSE for up to 7
days (CSE and culture medium were replaced every 24 h) or
to 20% CSE for up to 24 h based on the release of LDH in
culture supernatants. No significant differences in LDH activi-
ties were observed in the culture supernatants between the
CSE and control group (LDH cytotoxicity assay; Cayman,
Spain, data not shown).
‘Acute’ effects of CSE to compromise CBF of differentiated
human bronchial epithelial cells were explored in ‘short-term
incubations’ (up to 24 h), while ‘chronic’ effects of CSE
entailing a loss in cilia were investigated in long-term incu-
bations (up to 7 days).
Roflumilast N-oxide was added at 0, 2 or 1000 nM at
30 min before CSE if not indicated otherwise; 0 nM corre-
sponds to vehicle (0.1% DMSO), 2 nM corresponds to the free
plasma concentrations (unbound to plasma protein) after
repeated, oral, once-daily dosing of roflumilast at the clinical
dose of 500 mg·day-1 (Bethke et al., 2007; Hatzelmann et al.,
2010), and at 1000 nM roflumilast N-oxide completely and
selectively inhibits PDE4 (Hatzelmann and Schudt, 2001).
The half-maximum potency of roflumilast N-oxide to inhibit
PDE4 amounts to 2 nM (Hatzelmann and Schudt, 2001).
In experiments exceeding a 24 h incubation period, both
roflumilast N-oxide or vehicle and CSE were replaced every
24 h.
In some experiments, theophylline was added at 10 mM,
forskolin at 10 mM, dbcAMP at 1 mM, apocynin at 100 mM or
N-acetylcysteine at 1 mM.
Both test compounds and CSE were added to the basola-
teral media and at the apical surface. Because manipulations
at the apical surface may affect cilia physiology, all incuba-
tions with vehicle controls were run under identical condi-
tions as those of the CSE and test compounds (e.g. identical
volumes of medium comprising test compounds/CSE of 25 mL
were added to the apical surface throughout all conditions, for
the basolateral compartment the volume was kept at 500 mL
for all conditions). In control experiments where vehicles/
medium (instead of test compounds/CSE) were added to the
apical surface of differentiated human bronchial epithelial
cells over a maximum of 7 days (including daily replacement
procedures, as indicated), the number of ciliated cells and
expression of cilia markers were found to be not different from
cultures of differentiated human bronchial epithelial cells in
the absence of the manipulations at the apical surface.
CBF and functional ciliated cell analysis
Measurement of CBF and functional ciliated cell analysis
followed previously described protocols (Armengot et al.,
2010). Briefly, cells were imaged with a digital high speed
video (DHSV) imaging technique using a Nikon Eclipse TS100
microscope equipped with a 40¥ Nikon phase-contrast objec-
tive, providing a final optical gain of ¥400. A CCD camera
(Digital Quad High Speed Progressive Scan Camera, JAI
CV-A33 CL) at 128 frames s-1 was used. Video signals were
digitized and processed using appropriate software. Contrast-
enhanced video images were selected and the light intensity
of the selected pixels was recorded on a frame-by-frame basis.
In addition, the magnitude spectrum from a fast Fourier
transformation of the variation of pixel intensity signal was
analysed in an average of six different regions of (3 ¥ 3 pixels)
the cilia in individual cells in a minimum of 10 cells per
experiment. CBF experiments were performed with cells sub-
merged in HBSS (Lonza, Cambridge, UK) at an apical volume
of 100 mL at room temperature (26°C).
The average number of ciliated cells with cilia motility in
relation to total cells was determined using the same tech-
nique as described above for CBF (Armengot et al., 2010). For
each experimental condition, a minimum of 10 separate
fields was captured (approximately 500 cells per field in ¥400
augmentations). Cells with cilia motility were identified by
the movement of cilia detected by DHSV. Data were calcu-
lated as the average number of cells with cilia motility per
field and expressed as % of control.
Real time RT-PCR
Total RNA was isolated from differentiated bronchial epithe-
lial cells using TriPure® Isolation Reagent (Roche, Indianapo-
lis, IN, USA). Reverse transcription was performed in 300 ng
of total RNA with TaqMan reverse transcription reagents kit
(Applied Biosystems, Madrid, Spain); 1.5 mL of the resulting
cDNA was amplified using specific primers and probes
included in TaqMan Gene Expression Assays (Assay-On-
Demand; Applied Biosystems) for IL-13 (IL-13,
Hs99999038_m1), forkhead transcription factor 1 (Foxj1,
Hs00230964_m1), axonemal dynein intermediate polypep-
tide 2 (Dnai2, Hs01001551_m11), b-tubulin IV (b-tubulin IV,
Hs00893144_g1) the NADPH oxidases NOX2 (NOX2,
Hs01553391_m1), DUOX1 (DUOX1, Hs00213694_m1) or
DUOX2 (DUOX2, Hs00204187_m1) in a 7900HT Fast Real-
Time PCR System (Applied Biosystems). Relative quantifica-
tion of these different transcripts was determined with the
2-DDCT method using GAPDH as an endogenous control
(Applied Biosystems; cat no: 4352339E).
To determine the relative expression of the PDE4A, PDE4B
and PDE4D subtypes as well as of the NADPH oxidase NOX1,
p47phox and p67phox SYBR Green real-time PCR was used.
We designed the PDE4 primers between the exons 11 and 12
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of the different PDE4 transcripts in order to recognize the
different isoforms (Table 1). The percentage primer efficiency
and correlation coefficients of the SYBR Green primers was
calculated and accepted for efficiencies 100  10%. The
amplification specificity for each RT-PCR analysis was con-
firmed by melting curve analysis; 4 mL of cDNA was added to
19 mL of reaction mixture containing 7 mL H2O, 10 mL Quanti-
Tect® SYBR® Green PCR Master Mix (Qiagen, Crawley, UK)
and 1 mL each of forward and reverse primers (10 mM)
(Table 1). Relative quantification of transcript levels (com-
pared with control groups) was determined by evaluating the
expression as 2-DDCT as described above.
DCF fluorescence measurement of reactive
oxygen species
2′,7′-Dichlorodihydrofluorescein diacetate (H2DCF-DA;
Molecular Probes, Manchester, UK) is a cell-permeable com-
pound that following intracellular ester hydrolysis is oxidized
to fluorescent 2′,7′-dichlorofluorescein (DCF) by O2·- and
H2O2, and can therefore be used to monitor intracellular
generation of reactive oxygen species (ROS) (Trayner et al.,
1995). To quantify ROS levels, polarized human bronchial
epithelial cells were washed twice with PBS and incubated for
30 min with 50 mM H2DCF-DA diluted in Opti-MEM with
10% fetal calf serum in the presence or absence of roflumilast
N-oxide, dbcAMP or the antioxidant NAC. Then, cells were
again washed twice with PBS to remove remaining H2DCF-DA
and stimulated with CSE in the presence or absence of the
same drugs indicated before for 30 min. Five randomly
selected fields per condition were measured for fluorescent
intensity using an epifluorescence microscope (Nikon
Eclipse-TE-200, Tokyo, Japan) with filter set for fluorescein
isothiocyanate (FITC). Subsequent image capture and
analysis was performed using Metafluor® 5.0 software (Ana-
lytical Technologies, San Francisco, CA, USA). Results were
expressed as DCF fluorescence in relative fluorescence units.
Immunofluorescence and ciliated cell count
Foxj1, Dnai2 and b-tubulin IV in differentiated human bron-
chial epithelial cells were analysed by immunofluorescence.
To this end, transwell inserts of air-liquid interface-cultured
human bronchial epithelial cells were fixed in paraformalde-
hyde (4%) for 45 min and embedded in Tissue-Tek® OCT™
cryosectioning compound (Sakura Finetek Europe BV, Leiden,
the Netherlands). Blocks were cut into 10 mm thick sections,
permeabilized in Triton X 100 (0.1% in PBS) for 5 min,
blocked in 10% goat serum in PBS and immunostained with
mouse anti-human monoclonal antibodies against either
Foxj1 (1:50; ab95697; Abcam, Cambridge, UK), Dnai2 (1:50;
ab72746; Abcam) or b-tubulin IV (1:100; Clone ONS.1A6;
Sigma, Gillingham, UK) for 24 h at 4°C, followed by a second-
ary FITC (Foxj1, Dnai2) or rhodamine (b tubulin IV) conju-
gated anti-mouse IgG antibody (1:100; Molecular Probes,
Manchester, UK), and finally 4′,6-diamidino-2-phenylindole
(DAPI) (2 mg·mL-1) to mark nuclei (Molecular Probes, Leiden,
the Netherlands). The cells were visualized at excitation/
emission of 485/525 nm (FITC), or 570/590 nm (rhodamine)
or 350/470 nm (DAPI) with a ¥400 magnification in a TE-200
epifluorescence microscope (Nikon Eclipse-TE-200).
The antibodies against Foxj1, Dnai2 and b-tubulin IV
showed a single band in Western blots of appropriate cell or
tissue lysates within a large range from 25 to 250 kDa accord-
ing to information given by the manufacturer. This was con-
firmed by our own studies wherein lysates of differentiated
human bronchial epithelial cell single bands at the appropri-
ate molecular weights between 25 and 250 kDa were found.
No other bands were detected. The manufacturer recom-
mended both antibodies as appropriate for immunohisto-
chemistry/immunofluorescence.
The number of ciliated cells was quantified based on
immunofluorescent labelling for b-tubulin IV, a commonly
used cilia marker. To this end, whole transwell inserts of
differentiated human bronchial epithelial cells were fixed in
paraformaldehyde (4%) for 45 min, permeabilized with
Table 1
Primers for SYBR Green real-time quantitative reverse transcriptase polymerase chain reaction
Name Sequence (5-3) GenBank accession no Product size (bp)
PDE4A forward TCATGGCCGAGTTCTTCCAG NM_006202.2 193
PDE4A reverse TCCAAAGTGTCCAAGATCTCCTG
PDE4B forward ATTGTATCGGCAATGGACAGAC NM_002600.3 213
PDE4B reverse GTATCGAGAATGTCCTGAGCATC
PDE4D forward AGTTCTTCCAGCAGGGAGACC NM_000923.3 196
PDE4D reverse TCTCGATTGTCCTCCAGCG
NOX1 forward TGGAACAGGAGATGGAGGAATT NM_007052.4 174
NOX1 reverse CATTGTCCCACATTGGTCTCC
p47phox forward TGAGCCATACGTCGCCATC NM_000265.4 180
p47phox reverse GACACGTCTTGCCCTGACTTT
p67phox forward ACTACTGCCTGACTCTGTGGTGTG NM_000433.3 158
p67phox reverse GGTAGCCTCATAACTGAAGAGTGC
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Triton X 100 (0.1% in PBS) for 5 min, blocked with 10% goat
serum in PBS and immunostained with a primary mouse
anti-human b-tubulin IV antibody for 24 h (1:100; Clone
ONS.1A6; Sigma, Gillingham, UK). b-tubulin IV expressing
cells in whole transwell inserts were then visualized with a
secondary FITC-conjugated anti-mouse IgG antibody (1:100;
Molecular Probes, Manchester, UK). The cells were visualized
at excitation/emission of 485/525 nm with a ¥400 magnifi-
cation in a TE-200 epifluorescence microscope (Nikon
Eclipse-TE-200).
To determine the percentage of ciliated cells present in
untreated and treated bronchial epithelial air-liquid interface
cultures, three transwell inserts each from control cells and
treated cells were examined. Ciliated cells were identified by
morphometric analysis of the b-tubulin IV positively staining
cilia on the cell surface as previously outlined (Look et al.,
2001). The percentages of airway luminal cells that expressed
b-tubulin IV were calculated visually using 10 regions per
Transwell insert. Results are expressed as % b-tubulin
IV-positive cells. The specificity of the immunostaining was
confirmed by substituting the primary antibody with an irrel-
evant mouse IgG or by omitting the primary antibody. No
positive immunostaining was observed in these controls
(data not shown).
Western blot
Western blot analysis was used to detect Foxj1, Dnai2,
b-tubulin IV and PDE4B proteins in differentiated bronchial
epithelial cells. Cells were scraped from air-liquid interface
transwell inserts and lysed on ice with a lysis buffer consist-
ing of 20 mM Tris, 1 mM EDTA, 150 mM NaCl, 0.1% Triton
X-100, 1 mM dithiothreitol (DTT) and 1 mg·mL-1 pepstatin A
supplemented by a complete protease inhibitor cocktail. The
Bio-Rad assay (Bio-Rad Laboratories Ltd, Herts, UK) was used
to quantify the level of protein in each sample to ensure
equal protein loading. SDS-PAGE was used to separate the
proteins according to their molecular weight. Briefly, 20 mg
of protein (denatured) mixed with 2¥ loading buffer [com-
prising 160 mM Tris HCl (pH 6.8), 4% SDS, 20% glycerol,
1.4 mM b-mercaptoethanol, 0.04% bromophenol blue],
along with a molecular weight protein marker (Bio-Rad
Kaleidoscope marker; Bio-Rad Laboratories), was loaded onto
an acrylamide gel consisting of a 5% acrylamide stacking gel
on top of a 12% acrylamide resolving gel and run through
the gel by application of 100 V for 1 h. Proteins were
transferred to a PVDF membrane using a wet blotting
method. The membrane was blocked with 5% Marvel in
PBS containing 0.1% Tween20 and then probed with
either mouse anti-human Foxj1 (1:1000; Abcam), or
Dnai2 (1:1000; Abcam) or b-tubulin IV (1:1000; Sigma, Gill-
ingham, UK) monoclonal antibodies, a goat anti-human
PDE4B (1:1000; Sigma, Gillingham, UK) polyclonal antibody
and a rabbit anti-human b-actin polyclonal antibody
(1:1000; Sigma, Gillingham, UK) as housekeeping reference,
followed by the corresponding peroxidase-conjugated sec-
ondary (1:10.000) antibody. The enhanced chemilumines-
cence method of protein detection using ECL-plus (GE
Healthcare, Amersham Biosciences, Manchester, UK) was
used to detect labelled proteins. Quantification of protein
expression was performed by densitometry relative to
b-actin expression using the software GeneSnap version 6.08
(Cambridge, UK).
cAMP assay
For measurements of cellular cAMP content following incu-
bations with CSE or roflumilast N-oxide as indicated, culture
medium was removed and the cells were washed with PBS.
Then, cells were lysed and the intracellular cAMP content was
determined with the cAMP Biotrak enzyme immunoassay
system according to manufacturer’s instructions (Amer-
sham). Results are expressed as fmol cAMP mg-1 protein (per
insert).
PKA activity
Differentiated human bronchial epithelial cells were incu-
bated with roflumilast N-oxide or vehicle followed by CSE.
After 24 h, cells were washed with PBS and lysed with a lysis
buffer (20 mM MOPS, 50 mM b-glycerolphosphate, 50 mM
sodium fluoride, 1 mM sodium vanadate, 5 mM EGTA,
2 mM EDTA, 1% NP40, 1 mM DTT, 1 mM benzamidine,
1 mM PMSF, and 10 mg·mL-1 leupeptin and aprotinin); 2 mg of
total protein was used to determine PKA activity. PKA activity
was measured using a colorimetric PKA Activity Assay Kit
(Assay Designs, Farmingdale, NY, USA) according to manu-
facturer’s instructions. Briefly, the non-radioactive, solid-
phase ELISA is based on the PKA-dependent phosphorylation
of a highly specific substrate attached to the assay plate that
in its phosphorylated form is detected by a specific antibody.
Results are expressed as x-fold of the PKA activity in untreated
human differentiated bronchial epithelial cells.
PDE activity assay
Following air-liquid interface culture as described above, dif-
ferentiated human bronchial epithelial cells were incubated
with CSE (10%) for 24 h. Then cells were scraped, lysed
and homogenized in a buffer containing 50 mM Tris-HCl
(pH 7.8), 150 mM NaCl, 10 mM MgCl2, 10 mM
2-mercaptoethanol, 1 mM EGTA, 50 mM sodium fluoride, 1%
Nonidet P-40, 0.5% sodium deoxycholate, 0.5% SDS, 50 mM
benzamidine, 0.5 mg·mL-1 leupeptin, 0.7 mg·mL-1 pepstatin,
4 mg·mL-1 aprotinin, 10 mg·mL-1 soybean trypsin inhibitor
and 2 mM PMSF. The homogenate was centrifuged at
14.000 g for 10 min. PDE activities were measured in super-
natants using 15 mg of protein per condition (protein was
determined using the Bio-Rad assay as described in the
section on Western blotting).
Total PDE and PDE4 activities were measured as described
previously (Thompson et al., 1974) with modifications
(Cortijo et al., 1996; Singh et al., 2003). Briefly, a reaction
mixture with a final volume of 200 mL consisting of
40 mM Tris-HCl (pH 8.0), 10 mM MgCl2, 1.25 mM
2-mercaptoethanol, 20 mg bovine serum albumin, 1 mM
[3H]-cAMP and 25 mL of the 14.000 g cell extract supernatant
(comprising 15 mg of protein with PDE activity) was incu-
bated at 37°C for 15 min. Then 200 mL of 40 mM Tris-HCl
(pH 7.5) was added and reactions were terminated by boiling
in a water bath for 3 min. Once the reaction mixture had
returned to room temperature, 50 mL of Crotalus atrox venom
(1 mg·mL-1) was added comprising 5′ nucleotidase. Following
an incubation for 10 min at 37°C allowing all [3H]-5′-AMP
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being converted into [3H]-adenosine, an anion exchange
resin was used to separate uncharged [3H]-adenosine from
negatively charged [3H]-cAMP. To this end, 500 mL of a 1:3
slurry of Bio-Rad resin (AG 1-X2, 200–400 mesh) in
de-ionized water was added to each one of the assay tubes.
After centrifugation for 10 min, 250 mL aliquots of the super-
natant were collected and counted in a liquid scintillation
counter. To determine PDE4 activity, assays were run in the
presence of roflumilast N-oxide at 1 mM (that completely and
selectively blocks all PDE4) or vehicle (0.1% DMSO). PDE4
was calculated as the difference of PDE activity measured in
the presence or absence of roflumilast N-oxide. PDE enzy-
matic activity and is expressed as pmol cAMP hydrolysed
min-1 mg-1 protein.
Results were corrected for blank values (measured in the
presence of denatured proteins) that remained below 2% of
total radioactivity. cAMP degradation was <25% of the
amount of substrate added and, thus, was in the linear range.
ELISA
IL-13 protein was analysed in culture supernatants of differ-
entiated human bronchial epithelial cells by using a commer-
cially available enzyme-linked immunosorbent assay kit
(R&D Systems, Abingdon, Oxon, UK) according to the manu-
facturer’s protocol.
Neutralization of IL-13
In some experiments, a neutralizing antibody against IL-13
was used to investigate the role of IL-13 in CSE-induced loss
in Foxj1, Dnai2 and b tubulin IV protein expression. To this
end, a rat anti-human IL-13 monoclonal antibody (mAb-IL-
13; clone JES 10-5A2, affinity purified, azide free and low
endotoxin, acquired from BD Pharmingen™, Madrid, Spain)
was used at 150 ng·mL-1 that should result in > 95% neutrali-
zation of IL-13. This antibody or its respective isotype control
(rat IgG1 at 150 ng·mL-1) was added to the basolateral and
apical compartment of the differentiated human bronchial
epithelial cell cultures from 30 min before initiation of CSE
exposure over 3 days. Following cell lysis and protein extrac-
tion, Foxj1, Dnai2 and b tubulin IV were detected by Western
blotting as described before.
Statistical analysis
Data are presented as mean  SEM of n experiments. Statis-
tical analysis of data was performed by ANOVA followed by
Bonferroni test (GraphPad Software Inc, San Diego, CA, USA).
Significance was accepted when P < 0.05.
Materials
Roflumilast N-oxide (N-(3,5-dichloro-1-oxypyridin-4-yl)-3-
cyclopropylmethoxy-4-difluoromethoxybenzamide) was syn-
thesized by Nycomed GmbH, Konstanz, Germany. Unless
indicated otherwise, all other reagents used were obtained
from Sigma (Chemical Co, Madrid, Spain). Roflumilast
N-oxide or forskolin was dissolved in dimethyl sulfoxide
(DMSO) at 10 mM stock concentration. Theophylline was
dissolved in HCl 0.1 M at 100 mM stock concentration.
Several dilutions of the stocks were performed with cell
culture medium. The final concentrations of DMSO (0.1%) or
HCl (10 mM) in the cell culture did not affect cellular func-
tions. Other chemicals [dibutyryl cAMP (dbcAMP), apocynin,
N-acetyl cysteine (NAC)] were dissolved in medium.
Results
Short-term effects of roflumilast N-oxide and
forskolin on CBF in differentiated human
bronchial epithelial cells
Adding the adenylyl cyclase activator forskolin (10 mM) or
the PDE4 inhibitor roflumilast N-oxide (2 nM, 1 mM) to well-
differentiated cultures of ciliated human bronchial epithelial
cells resulted in a rapid increase in CBF (Figure 1A,B). CBF
peaked within 3 min after addition of forskolin but about
70% of this increment was lost after 30 min and CBF returned
to baseline values another 90 min later. Roflumilast N-oxide
at 1 mM (corresponding to complete and selective inhibition
of PDE4) reproduced the rather immediate rise in CBF that,
however, persisted when monitored over 3 h. Roflumilast
N-oxide at 2 nM [corresponding to about half-maximum
inhibition of PDE4 (Hatzelmann and Schudt, 2001) and free
plasma concentrations in man following clinical dosing of
roflumilast (Bethke et al., 2007)] resulted in a gradually
increasing rise in CBF attaining a maximum at 60 min fol-
lowing addition of the PDE4 inhibitor that corresponded to
about half the peak CBF found with 1 mM roflumilast
N-oxide. Again, the increase in CBF was maintained over the
remaining 2 h observation period.
Because endogenously produced adenosine may regulate
the homeostasis of bronchial epithelial cells (Rollins et al.,
2008) and adenosine (by stimulating A2B receptors) was
reported to augment CBF in airway epithelial cells
(Lazarowski and Boucher, 2009; Allen-Gipson et al., 2011),
the effects of theophylline at 10 mM, a concentration at
which the xanthine is a non-specific antagonist to adenosine
receptors including A2B but does not interfere with PDE activi-
ties, were studied. Strikingly, there was a rapid and persistent
fall in CBF following theophylline (Figure 1C). Then roflumi-
last N-oxide (2 nM) was added to the incubations with theo-
phylline once this fall in CBF had reached a robust plateau
(1 h after theophylline). In the presence of theophylline, the
PDE4 inhibitor restored CBF to baseline, but not above
(Figure 1C,D). On the other hand, the increment in CBF
secondary to roflumilast N-oxide at 2 nM was abolished by
theophylline (Figure 1D).
Effects of roflumilast N-oxide and forskolin
on the rapid loss of CBF following exposure
of differentiated human bronchial epithelial
cells to CSE
In order to determine the short-term effect of CSE on CBF,
differentiated bronchial epithelial cells were incubated with
CSE at 10% for up to 3 h and CBF was regularly monitored.
CSE almost instantaneously impaired CBF and this reduction
was maintained over at least 3 h. Forskolin, added from
60 min after CSE, resulted in a rapid, yet partly transient
recovery in CBF (Figure 2A). Full and maintained recovery
from the CSE-induced loss in CBF, however, emanated from
roflumilast N-oxide at 1 mM while the PDE4 inhibitor at the
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Figure 1
Forskolin and roflumilast N-oxide rapidly increased CBF of differentiated human bronchial epithelial cells, effects of theophylline. Following an
initial 20 min baseline period, differentiated bronchial epithelial cells (D-BECs) were incubated with forskolin at 10 mM (A), or roflumilast N-oxide
(RNO) at 2 nM or 1 mM (B), or theophylline (THEO) at 10 mM followed by roflumilast N-oxide (2 nM) (C) or vehicle (baseline), and ciliary beat
frequency (CBF) was monitored for up to 3 h. (D) D-BECs were incubated with vehicle (control), or 2 nM RNO, or THEO at 10 mM, or THEO
followed by RNO (from 80 min) (THEO→RNO), or RNO followed by THEO (from 80 min) (RNO→THEO), and the CBF assessed at 3 h is depicted.
CBF was measured by DHSV microscopy and quantified by Fourier transformation as detailed in Methods. Results are shown as the means  SEM
of three experiments per donor based on cultures from two to four different donors per condition. Vehicle (0.1% DMSO for RNO or forskolin and
10 mM HCl for THEO) was included in the controls and did not affect CBF over the observation period. (A and B) *P < 0.05 versus baseline. (C)
*P < 0.05 versus baseline; #P < 0.05 versus THEO. (D) *P < 0.05 versus control; #P < 0.05 versus RNO; P < 0.05 versus THEO.
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concentration of 2 nM resulted in a more gradually improved
CBF approaching fully restored CBF at the end of the 3 h
monitoring period (Figure 2B).
Because cAMP is a critical regulator of CBF, the potential
effects of CSE on the cAMP content of differentiated human
bronchial epithelial cells were explored next. Exposure to CSE
at 10% reduced the initial cAMP content by 46% within
5 min and this had not recovered 1 h later, whereas cAMP
content did not change over this time period in appropriate
controls (Figure 2C). Roflumilast N-oxide (2 nM) when added
at 15 min following initiation of CSE exposure rescued the
cells from this loss in cAMP; the cAMP content was signifi-
cantly elevated to almost control levels after 45 min
(Figure 2C). This effect of was more or less in parallel to its
effects on CBF (Figure 2B).
In the absence of CSE, roflumilast N-oxide at 2 nM
enhanced the cellular cAMP content by about 1.7-fold within
15 min and this remained sustained over at least another
30 min (Figure 2C).
Long-term exposure (24 h) to CSE impaired
CBF: effects of roflumilast N-oxide and role
of PKA
When differentiated human bronchial epithelial cells were
exposed to CSE for 24 h, CBF was concentration- depend-
ently compromised (Figure 3A) in the absence of cytotoxicity
(assessed by LDH release in separate experiments). Appar-
ently, CBF deteriorated more markedly when CSE was present
for 24 h compared with 3 h (Figure 2A,B). The following
experiments were then conducted with CSE at 10%. The
concomitant presence of roflumilast N-oxide at 1 mM along
with CSE for 24 h prevented the loss in CBF secondary to the
smoke extract. The PDE4 inhibitor at 2 nM resulted in
approximately 68% recovery of CBF (Figure 3B). Quenching
ROS by adding apocynin (100 mM) or N-acetylcysteine
(1 mM) reversed the loss in CBF following a 24 h exposure to
CSE (10%) by 70–80% (Figure 3C).
Next, the effects of CSE on cAMP and PKA were investi-
gated under these experimental conditions. In differentiated
human bronchial epithelial cells exposed to tobacco smoke
for 24 h, the cAMP content (Figure 3D) and in parallel PKA
activity (Figure 3E) were both reduced compared with con-
trols, and for cAMP the loss was comparable to that observed
after 5 min incubation with CSE (Figure 2C). The additional
presence of roflumilast N-oxide at 2 nM almost restored the
cAMP content (Figure 3D) and PKA activity (Figure 3E), while
both cAMP and PKA activity recovered to higher than base-
line with 1 mM roflumilast N-oxide; this also occurred with
dbcAMP, a cAMP analogue serving as a positive control
(Figure 3D,E).
Regulation of PDE4 expression by CSE:
effects of roflumilast N-oxide and role of
oxidative stress
The loss in cAMP content secondary to CSE exposure for 24 h
prompted us to analyse the activity and expression of PDE4,
well-known as the prominent cAMP hydrolysing PDE in
human bronchial epithelial cells. Firstly, exposure of differ-
entiated bronchial epithelial cells to CSE at 10% for 24 h
induced about a twofold increase in PDE4 activity
(Figure 4A), probably as a result of an up-regulation in the
expression of PDE4B. Indeed, of the PDE4 subtypes analysed,
mRNA transcripts for PDE4B were most markedly increased
by 2.8-fold over control (P < 0.05), while the 1.4-fold and
1.3-fold increment in PDE4A and D transcripts, respectively,
remained below significance (Figure 4B). Strikingly, quench-
ing ROS by apocynin (100 mM) or N-acetylcysteine (1 mM)
reversed the CSE-induced increment in PDE4B transcripts
(Figure 4C). As an enhancement in the levels of cAMP may
prevent CSE-induced oxidative stress (as exemplified in
Figure 5), next the effects of dbcAMP (1 mM) on PDE4B
expression were investigated. The cAMP analogue prevented
the CSE-induced increment in PDE4B transcripts (Figure 4D).
In line with this result, inhibiting PDE4 (roflumilast N-oxide
Figure 2
CSE triggered a rapid loss of CBF in differentiated human bronchial epithelial cells, an effect which was reversed by forskolin and roflumilast
N-oxide (A, B). Following an initial 20 min baseline period, differentiated bronchial epithelial cells (D-BECs) were exposed to CSE at 10% for up
to 3 h. From the time point the reduction in CBF was optimal (at 80 min), forskolin (FSK) at 10 mM (A) or roflumilast N-oxide (RNO) at 2 nM or
1 mM (B), or vehicle was added. CBF was monitored for 3 h by DHSV and quantified by Fourier transformation as detailed in Methods. Results are
shown as the means  SEM of three experiments per donor based on cultures from two to four different donors per condition. *P < 0.05 versus
control, #P < 0.05 versus CSE. CSE rapidly reduced cAMP content in differentiated human bronchial epithelial cells (C). D-BECs were exposed to
vehicle (baseline), RNO at 2 nM, CSE at 10% followed by vehicle or RNO (2 nM) at the indicated times and cellular cAMP content was measured
at different time points. Results are shown as the means  SEM from cultures of two donors in duplicates. *P < 0.05 versus control.
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at 1 mM) abolished the CSE-induced increment in PDE4B
transcripts (Figure 4E) and protein (Figure 4F). Roflumilast
N-oxide at 2 nM modestly reduced the increment in PDE4B
transcripts secondary to CSE (Figure 4E). At this concentra-
tion, the PDE4 inhibitor was not found to significantly reduce
PDE4B protein based on the densitometric analyses
(Figure 4F).
Effects of roflumilast N-oxide on CSE-induced
intracellular ROS and NADPH oxidases in
differentiated human bronchial epithelial cells
The role of ROS and its possible regulation by roflumilast
N-oxide was further addressed. Intracellular ROS was quanti-
fied as DCF following oxidation from H2DCF-DA. Exposure of
differentiated human bronchial epithelial cells to CSE at 10%
for 30 min resulted in an approx. fourfold increase in DCF
accumulation over control. Pre-incubation with roflumilast
N-oxide concentration-dependently reduced the increment
in DCF accumulation by about 53 and 86% at 2 nM and
1 mM, respectively (Figure 5). dbcAMP (1 mM) reproduced the
reduction in DCF accumulation observed with the PDE4
inhibitor. Finally, NAC (1 mM) serving as a control prevented
DCF accumulation triggered by CSE (Figure 5).
Exposure of differentiated human bronchial epithelial
cells to CSE at 10% for 24 h up-regulated the expression of
the NADPH oxidase isoenzymes NOX1, NOX2 (gp91phox)
and DUOX2 (Figure 6) while DUOX1 was not affected (data
not shown). This up-regulation was reduced by roflumilast
N-oxide at 2 nM and 1 mM and dbcAMP at 1 mM. Quenching
of ROS by apocynin (100 mM) or NAC (1 mM) also suppressed
CSE-triggered expression of the NADPH oxidase isoenzymes
(Figure 6). Finally, CSE (10%) for 24 h enhanced the expres-
sion of the p47phox (2.5-fold) and p67phox (threefold)
cytosolic components required for assembling the active
NOX2 NADPH oxidase complex that again was reversed by
the PDE4 inhibitor or the ROS quenchers (data not shown).
Loss of ciliated bronchial epithelial cells by
CSE: effects of roflumilast N-oxide
Differentiated human bronchial epithelial cells were exposed
to CSE at different concentrations (0–10%) and time periods
(1, 3, 5 and 7 days). Then, the average number of cells with
cilia motility was determined by DHSV followed by Fourier
transformation. Under control conditions (0% CSE), the
average number of cells with cilia motility remained
unchanged over 7 days. Exposure to CSE concentration- and
Figure 3
Roflumilast N-oxide reversed the CSE-induced persistent loss of CBF in differentiated human bronchial epithelial cells (A-C), role of cAMP (D), PKA
(E). Differentiated human bronchial epithelial cells (D-BECs) were exposed to CSE at 0–20% for 24 h (A), or pre-incubated for 30 min with
roflumilast N-oxide at 2 nM or 1 mM (B) or with apocynin (ACY) at 100 mM or with at NAC at 1 mM (C) or vehicle (B, C) and then exposed to
CSE at 10% for 24 h. Then CBF was measured by DHSV and quantified by Fourier transformation as detailed in Methods. Results are shown as
the means  SEM of cultures from two to four donors and three experiments per donor. In (D) and (E), D-BECs were pre-incubated for 30 min
with roflumilast N-oxide at 2 nM or 1 mM or with dbcAMP (1 mM) before exposure to 10% CSE. Cellular cAMP content (D) and PKA (E) were
assessed after 24 h as described in Methods. Results are depicted as means  SEM of cultures from three donors and three experiments per donor.
*P < 0.05 versus control, #P < 0.05 versus CSE.
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time-dependently reduced the average number of cells with
cilia motility, which was significant after 3 days of incubation
with CSE at 2.5% (about 30% inhibition), and reached a
maximum of about 75% inhibition versus control after 7 days
of incubation with CSE at 10% (Figure 7A, left panel). Mor-
phologically, differentiated bronchial epithelial cells exposed
to CSE adopted a flattened and elongated phenotype with
fragmented cilia.
The additional presence of roflumilast N-oxide at 2 nM or
1 mM partially prevented the loss in bronchial epithelial cells
endowed with motile cilia elicited by incubation with 10%
CSE for 3 days. Indeed, the approx. 67% reduction of cells
with cilia motility following CSE compared with control was
diminished by 38 and 67% with roflumilast N-oxide at 2 nM
and 1 mM, respectively (Figure 7A, right panel).
In parallel, immunostaining against the cilia marker
b-tubulin IV was performed to monitor the occurrence of cilia
on bronchial epithelial cells. Incubation with 10% CSE for 3
days reduced the percentage of cells positively staining for
b-tubulin IV by about 60%. Roflumilast N-oxide at 2 nM and
1 mM concentration-dependently prevented the loss of this
cilia marker by 34 and 62%, respectively (Figure 7B), which is
in the range comparable to findings from acquisition of the
average of cells with cilia motility.
Figure 4
CSE up-regulates PDE4B expression and PDE4 activity in differentiated human bronchial epithelial cells: Effects of roflumilast N-oxide and role of
ROS. Differentiated bronchial epithelial cells (D-BECs) were exposed to CSE (10%) or medium (control) for 24 h. (A) Total cAMP hydrolysing PDE
and PDE 4 activity following incubation of differentiated bronchial epithelial cells were measured in cell lysates. PDE4 activity was calculated as
the difference in PDE activity measured in the presence and absence of roflumilast N-oxide (1 mM). Data are the mean SEM (n = 3 per condition;
*P < 0.05 versus control). (B) Relative expression levels of mRNA transcripts for PDE4A, B and D subtypes were determined by real-time quantitative
RT-PCR using the SYBR Green protocol as described in Methods. In (C–F), D-BECs were pre-incubated (30 min) with either apocynin at 100 mM
(C), or NAC at 1 mM (C), or dbcAMP at 1 mM (D), or roflumilast N-oxide at 2 nM or 1 mM (E, F), or vehicle before exposure to CSE at 10% for
24 h. In (C, D, E), relative expression levels of PDE4B mRNA transcripts are shown. In (F), expression of PDE4B protein is depicted. Cells were lysed
and proteins separated by SDS-PAGE followed by blotting and detection using a PDE4B-specific antibody as detailed in Methods. A representative
Western blot and results from densitometric evaluations are illustrated. Means  SEM of D-BEC cultures from three donors and two experiments
per donor are shown (B–F). *P < 0.05 versus control, #P < 0.05 versus CSE.
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Effects of CSE and roflumilast N-oxide on
Foxj1 and Dnai2 expression in human
bronchial epithelial cells
Foxj1 is a transcription factor that is critical for and a regu-
lator of the motile ciliogenic programme (Yu et al., 2008).
Therefore, the expression of Foxj1 along with the dynein
axonemal intermediate chain-2 (Dnai2) protein, required to
assemble the outer dynein arm of the motile cilia and
b-tubulin IV to mark cilia, was studied in human bronchial
epithelial cells. First, expression levels of Foxj1 and Dnai2
along with b-tubulin IV were monitored over the time of
transition from undifferentiated bronchial epithelial cells
into the differentiated phenotype comprising ciliated cells
under in vitro air-liquid interface culture conditions. Immun-
ofluorescence stainings in sections of bronchial epithelial
cells revealed a time-dependent increase in ciliated cells based
on apical staining for b-tubulin IV over 28 days of air-liquid
interface culture (Figure 8A). This time course for b-tubulin
IV staining was closely paralleled by immunofluorescent
labelling of Dnai2 and Foxj1. Indeed, while at day 7 after
instigating the differentiating culture conditions, immun-
ofluorescence for b-tubulin IV, Foxj1 and Dnai2 remained
virtually absent, a moderate level of cilia markers b-tubulin IV
and Dnai2 emerged apically located along with some Foxj1 in
the nuclear region at day 14 (Figure 8A). Four weeks of air-
liquid interface culture resulted in an almost complete cov-
ering of the cell layer by apical b-tubulin IV and Dnai2
staining corresponding to the high fraction of ciliated cells in
these cultures as depicted in Figure 7B. In parallel, the expres-
sion of Foxj1 in the nuclear region was further enhanced at
day 28 (Figure 8A). These progressive increases in the markers
of the ciliated cell phenotype were reflected in analyses of
total protein (Western blot) (Figure 8B) and mRNA
(Figure 8C). For example, transcripts for Foxj1, Dnai2 and
b-tubulin IV (Figure 8C) were significantly enhanced at day
14 and further increased to day 28 after initiation of the
air-liquid interface culture. That enhanced expression of
Foxj1 over time was paralleled by increased expression of the
cilia constituents Dnai2 and b-tubulin IV, and by the mor-
phological observation of cells equipped with motile cilia is
in line with the critical role this transcription factor has in the
process of differentiation towards ciliated human bronchial
epithelial cells.
Next, differentiated human bronchial epithelial cells were
exposed to CSE (at 10%) over 24–72 h and the expression of
Foxj1 and Dnai2 was assessed. Compared with baseline, CSE
resulted in a comparable decrease in Foxj1 (Figure 9A) and
Dnai2 (Figure 9B) mRNA transcript levels by about 40% at
24 h and 70% at 72 h exposure. This fall in mRNA levels of
two proteins required for motile cilia integrity precedes the
loss in cells with cilia motility following CSE exposure
(Figure 7A).
Addition of the PDE4 inhibitor roflumilast N-oxide at
2 nM or 1 mM concentration-dependently prevented the
decrease in the expression levels of Foxj1 (Figure 10A) and
Dnai2 (Figure 10B) following 3 days of exposure of differen-
tiated bronchial epithelial cells to CSE at 10% with respect to
Figure 5
Roflumilast N-oxide attenuates CSE-induced intracellular ROS generation in differentiated human bronchial epithelial cells. Differentiated human
bronchial epithelial cells (D-BECs) were loaded with H2DCF-DA in the presence of roflumilast N-oxide (RNO) at 2 nM or 1 mM, or dbcAMP at
1 mM, or NAC at 1 mM, or vehicle for 30 min. Excess H2DCF-DA was removed by washing with PBS. RNO, dbcAMP, NAC or vehicle was
appropriately replenished before cells were exposed to CSE at 10%. Following a 30 min incubation period, accumulation of fluorescent DCF was
assessed with fluorescence microscopy in a total of five fields per condition as detailed in Methods. (A) Representative microphotographs (scale
bar corresponds to 20 mm). (B) Quantitative evaluation of DCF fluorescence. Results in (B) represent the means SEM of cultures from two donors
and three experiments per donor. *P < 0.05 versus control, #P < 0.05 versus CSE. CTR, control.
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mRNA transcripts and protein. These observations are in line
with earlier findings that roflumilast N-oxide partly pre-
vented the loss in cells with cilia motility (Figure 7A) and
those labelled with b-tubulin IV (Figure 7B) secondary to
exposure of differentiated bronchial epithelial cells to CSE at
10% for 3 days. Roflumilast N-oxide (1 mM) did not affect
baseline Foxj1 and Dnai2 in cultures not exposed to tobacco
smoke.
Given the documented role of IL-13 in regulating the
number of ciliated cells and Foxj1 expression in differentiated
bronchial epithelial cells (Turner et al., 2011), the effects of
CSE and roflumilast N-oxide on the release of this cytokine
were analysed. Exposure of differentiated human bronchial
epithelial cells to CSE at 10% for 3 days resulted in a strong
increase in IL-13 mRNA and protein. Roflumilast N-oxide at
2 nM and 1 mM partly reduced these effects. Specifically, rof-
lumilast N-oxide diminished the approx. 3.8-fold increment
in the release of IL-13 induced by CSE by 34% at 2 nM and by
60% at 1 mM (Figure 11).
In order to further elucidate a potentially critical role of
IL-13 in CSE-induced down-regulation of ciliated cell
markers, the effects of a monoclonal antibody specifically
neutralizing human IL-13 (mAb-IL-13) were explored. The
neutralizing antibody partially prevented the reduced expres-
sion of Foxj1, Dnai2 and b-tubulin IV following CSE while
the isotype control was without effect (Figure 11C).
Discussion
Mucociliary malfunction may contribute to the progressive
decline of lung function in COPD (Agusti, 2005). Ciliary
beating and the fraction of ciliated cells within the bronchial
epithelial cells are among the critical determinants of muco-
ciliary clearance. Tobacco smoking is a major risk factor in
COPD.
The current in vitro study in air-liquid cultured, polarized
human bronchial epithelial cells reports that CSE triggers a
rapid and sustained reduction in CBF and a loss of ciliated
cells following long-term exposure. This compromised CBF
and ciliated cell phenotype was prevented by roflumilast
N-oxide, a PDE4 inhibitor. Indeed, roflumilast N-oxide
(2 nM, 1 mM) (i) triggered a rapid (10 min) and sustained
(at least 3 h) increase in CBF; (ii) reversed the decline in CBF
secondary to CSE (10%); and (iii) alleviated the loss in
ciliated cells caused by long-term (3 days) exposure to
CSE.
In ciliated cells, an increase in cAMP translates into
enhanced CBF attributed to PKA-dependent phosphorylation
of dynein light chain (Schmid et al., 2006; 2007; Salathe,
2007). Consequently, complete and selective inhibition of
PDE4 (1 mM roflumilast N-oxide) acting to enhance cAMP
triggered an immediate and persistent rise in CBF. Roflumilast
N-oxide at 2 nM [corresponding to the range of therapeutic
plasma levels (unbound to plasma proteins) following
repeated dosing of roflumilast at the clinical dose of
500 mg·day-1 in man (Bethke et al., 2007) and about 50%
inhibition of PDE4 (Hatzelmann and Schudt, 2001)] repro-
duced the persistent increase in CBF over 3 h; however, to a
lesser, about half-maximum extent, and with delayed time
course. The reason for this delayed time course is not clear
Figure 6
CSE up-regulates mRNA expression of NADPH oxidases NOX1,
NOX2 and DUOX2 in differentiated human bronchial epithelial cells
(D-BECs) that was reversed by roflumilast N-oxide (RNO). D-BECs
were pre-incubated with RNO at 2 nM or 1 mM, or dibutyryl cAMP at
1 mM (cAMP), or apocynin (ACY) at 100 mM, or NAC at 1 mM, or
vehicle for 30 min and then exposed to CSE (10%) for 24 h. mRNA
transcripts of NOX1, NOX2 and DUOX2 were quantified by real-time
quantitative RT-PCR as described in Methods. Results are given as
means  SEM of cultures from two donors and three experiments
per donor. *P < 0.05 versus control, #P < 0.05 versus CSE. CTR,
control.
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but may be attributed to a time-dependent concentration
gradient until equilibrium is attained at the axonemal com-
partment with the lower concentration.
That PDE4 inhibitors augment airway epithelial CBF has
been described previously (Cervin and Lindgren, 1998;
Wohlsen et al., 2010), although apparently not in air-liquid-
cultured, differentiated human bronchial epithelial cells. In
rat precision cut lung slices, the PDE4 inhibitors roflumilast
and rolipram increase CBF (Wohlsen et al., 2010) in line with
the results from the current study.
Cellular effects emanating from PDE4 inhibition require
prior cAMP synthesis. A candidate cAMP increasing molecule
released by bronchial epithelial cells into the periciliary
lining fluid is adenosine that enhances CBF (Lazarowski
and Boucher, 2009; Allen-Gipson et al., 2011). Conversely,
antagonism at adenosine receptors (10 mM theophylline)
reduced baseline CBF and compromised the increase in CBF
by roflumilast N-oxide (2 nM). On the other hand, the PDE4
inhibitor reversed the loss in CBF secondary to theophylline.
Therefore, aside from adenosine, other factors maintaining
cAMP synthesis may operate and in this context, a role of the
soluble, bicarbonate sensitive adenylyl cyclase cannot be
excluded (Schmid et al., 2007).
Theophylline (10 mM) is a non-specific antagonist at all
adenosine receptors, and in the current study, which of the
receptors was involved in the reduction of CBF was not inves-
tigated. However, published evidence indicates that of the
four adenosine receptors, the A2B receptor is apparently exclu-
sively involved in CBF regulation by adenosine. Firstly, in
ciliated bronchial epithelial cells, transcripts of the A2B recep-
tor were more abundant than of A2A or A3 receptors while
mRNA encoding for the A1 receptor was virtually absent
(Rollins et al., 2008). Secondly, in human nasal epithelial
cells, CBF is enhanced by 5′-(N-ethylcarboxamide)adenosine
(NECA) but not a selective A2A adenosine receptor agonist
(Morse et al., 2001). Thirdly, CBF in tracheal rings from mice
deficient in A2B receptors failed to respond to NECA while
mice deficient in either A1, A2A or A3 receptors displayed the
Figure 7
Roflumilast N-oxide (RNO) protected from loss of ciliated bronchial epithelial cells induced by CSE. In (A, left panel), differentiated bronchial
epithelial cells (D-BECs) were exposed to CSE at different concentrations (0–10%) and times (0–7 days). Medium was replenished with fresh CSE
every 24 h. Cells with cilia motility were identified based on DHSV as described in Methods. At each of the indicated times and concentrations
of CSE exposure, the average number of cells with cilia motility per field was then calculated based on captures from a minimum of 10 separate
fields and expressed as % of corresponding cilia motility obtained for non-treated cells at day 0 (= 100%) (control). In (A, right panel), D-BECs
were pre-incubated with RNO at 2 nM or 1 mM or vehicle for 30 min and then exposed to CSE at 10% for 3 days. Culture medium with fresh CSE
and RNO was replaced every 24 h. The average number of cells with cilia motility per field was determined as in (A), left panel. In (B), D-BECs
were pre-incubated with RNO and then exposed to CSE at 10% for 3 days as described in (A). b-tubulin IV was identified by immunofluorescent
labelling with a primary anti-b-tubulin IV antibody followed by a secondary FITC-conjugated antibody as detailed in Methods. Representative
microphotographs are depicted in the upper, left panel (scale bar 20 mm, original magnification ¥ 400) with zoomed pictures in the lower, left
panel. Results of the morphometric evaluation are shown in the right panel as the percentage of cells that expressed b-tubulin IV of total cells.
Results are given as means  SEM of cultures from two donors and three experiments per donor. *P < 0.05 versus control, #P < 0.05 versus CSE.
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expected increase in CBF following the non-selective adeno-
sine receptor agonist (Allen-Gipson et al., 2011).
Patients with COPD display compromised CBF (Piatti
et al., 2005). CS deteriorates CBF (Ballenger, 1960; Cohen
et al., 2009) probably as a result of enhanced axonemal PKCe
(Wyatt et al., 2000; Simet et al., 2010). In line with this, PKC
activators slow ciliary beating (Salathe, 2007).
In the current study, reduced CBF following CSE (5 min)
appeared to decline in parallel with cAMP. Therefore, the
notion is raised that aside from PKC activation, a decreased
Figure 8
Differentiation of human bronchial epithelial cells in air-liquid interface culture is associated with an increase in Foxj1, Dnai2 and b-tubulin IV.
Undifferentiated bronchial epithelial cells from monolayer cultures were plated on porous transwell inserts and differentiated in an air-liquid
interface culture for 28 days. (A) Immunofluorescence detection of Foxj1, Dnai2 and b-tubulin IV in sections prepared at days 7, 14 and 28 after
initiation of the air-liquid interface culture. Green staining (FITC) indicates the presence of Foxj1 or Dnai2, red staining (rhodamine) reflects
b-tubulin IV. Blue staining indicates cell nuclei (DAPI). Scale bar 30 mm. Representative sections are shown and no detectable staining was observed
for corresponding isotype controls. In (B) and (C), Western blots (B) and relative mRNA expression levels (C) for Foxj1, Dnai2 or b tubulin IV at
day 7, 14 and 28 following initiation of the air-liquid interface culture are shown. Western blots are a representative of three independent
experiments. The mRNA expression levels were quantified by real-time RT-PCR and evaluated as the x-fold change versus control (immediately
before initiation of the air-liquid interface culture) using the 2-DDCt formula with GAPDH as endogenous standard. Results from mRNA analyses
represent the means  SEM of cultures from three donors and three experiments per donor. *P < 0.05 versus control.
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cAMP content may contribute to the compromised CBF fol-
lowing CSE. The CSE-induced rapid loss in cAMP may origi-
nate from reduced synthesis, enhanced degradation or efflux.
Currently, the exact mechanism remains elusive. For
example, cAMP-degrading PDE activities (specifically PDE4)
may have been enhanced. Hydrogen peroxide, a component
of tobacco smoke (Nakayama et al., 1989), swiftly elevates the
activity of PDE4D3 attributed to PI3K and ERK-dependent
phosphorylations (Hill et al., 2006). In the current study, the
rapid reversal of CSE-induced loss in CBF by forskolin and
roflumilast N-oxide, shown to replenish intracellular cAMP
(as depicted in Figure 2C), may underpin the role of this
cyclic nucleotide in the regulation of CBF in the presence of
CSE.
Exposure of differentiated bronchial epithelial cells to CSE
for 24 h reduced CBF more markedly than after 3 h. Over this
period, CSE enhanced the expression of the NADPH oxidase
isoenzymes NOX1, NOX2 and DUOX2, but not DUOX1.
Hence, (long-term) up-regulation of NOXs (Figure 6) in addi-
tion to the (short-term) increase of ROS (probably as a result
of elevated NOX activity) following CSE (Figure 5) may
account for the more accentuated reduction of CBF after a
24 h exposure to CSE. Quenching intracellular ROS by NAC
or apocynin reversed the CSE (24 h)-induced loss in CBF,
underpinning a critical role for ROS in the compromised CBF.
Expression of NOX1 (Schneider et al., 2010), NOX2
(Schwarzer et al., 2004; Fink et al., 2008) and DUOX2 (Petry
et al., 2010) has been described in airway epithelial cells.
Bronchial epithelial NOX1 is up-regulated in COPD (Schnei-
der et al., 2010) and the expression of DUOX2 is increased in
smokers (Nagai et al., 2008). In vitro, in polarized human
bronchial epithelial cells, DUOX1 transcripts are not affected
by exposure to CSE (Lavigne and Eppihimer, 2005) as found
here. These authors further demonstrated enhanced intracel-
lular ROS after CSE exposure of bronchial epithelial cells,
confirming the current observations.
Roflumilast N-oxide prevented the suppression of CBF
induced by 24 h exposure to CSE. As the PDE4 inhibitor
diminished the short-term ROS formation (Figure 5) and the
expression of NOX isoforms (Figure 6) induced by CSE and
given the potential role of ROS to induce the loss in CBF
following CSE, one may postulate that inhibition of ROS
accounts for the potential of roflumilast N-oxide to reverse
the decrease in CBF following CSE.
It is likely that roflumilast N-oxide and dbcAMP dimin-
ished the rapid rise in CSE-induced ROS in differentiated
bronchial epithelial cells by inhibiting NOX activities. Such
an effect has been well documented in neutrophils (Hatzel-
mann and Schudt, 2001) and was recently reproduced in
human pulmonary artery smooth muscle cells where roflu-
milast N-oxide reduced U46619-triggered rapid ROS release
by curbing Rac1 activation, involved in the induction of
NOX1- and NOX2-dependent NADPH oxidase activities
(Muzaffar et al., 2008). In the same cells, roflumilast N-oxide
attenuates the enhanced expression of NOX1 induced by a
TXA2 analogue (Muzaffar et al., 2008). Essentially, the ability
of this PDE4 inhibitor to suppress ROS formation secondary
to CSE in differentiated human bronchial epithelial cells may
represent a critical mechanism potentially accounting for the
observed reversal of the CSE-induced enhanced expression of
NOX isoenzymes. Indeed, this up-regulation was prevented
when intracellular ROS was quenched by apocynin or NAC,
and earlier others suggested that superoxide itself may elevate
the expression of NOX2 in porcine pulmonary artery
endothelial cells (Muzaffar et al., 2006).
Earlier studies have shown that in smokers with COPD,
there was a rise in PDE4 in alveolar macrophages (Barber
et al., 2004). In the current study CSE (24 h) enhanced PDE4
activity and PDE4B expression. Roflumilast N-oxide and
dbcAMP reversed this up-regulated PDE4B expression. The
latter observation may allude to another level of PDE4 inhi-
bition but appears inconsistent with the view that cAMP
elevates PDE4B expression (Conti and Beavo, 2007).
However, processes in the current study are probably control-
led by ROS because apocynin and NAC prevented the CSE-
induced PDE4B up-regulation and roflumilast N-oxide and
dbcAMP suppressed ROS secondary to CSE. In support of this
notion, a ROS-dependent enhanced expression and activity
of PDE4 has recently been unveiled in human umbilical vein
endothelial cells (Muzaffar et al., 2012).
Figure 9
CSE provokes a loss of Foxj1 and Dnai2 expression in differentiated
human bronchial epithelial cells (D-BECs). D-BECs were exposed to
CSE at 10% or medium (control) for 24, 48 and 72 h and the levels
of Foxj1 (A) and Dnai2 (B) mRNA transcripts were quantified by
real-time RT-PCR. mRNA expression is evaluated as the x-fold change
versus control (medium) at the corresponding time points using the
2-DDCt formula with GAPDH as endogenous standard. Results are
shown as the means  SEM of cultures from two donors and three
experiments per donor. *P < 0.05 versus control.
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The F-box forkhead transcription factor Foxj1 (HFH-4) is a
master regulator of the motile ciliogenic programme (Yu
et al., 2008). In line with a previous study (Turner et al.,
2011), there was a time-dependent increase in Foxj1 mRNA
and protein over a 4 week period of air-liquid interface
culture from non-differentiated to ciliated bronchial epithe-
lial cells. In parallel, the expression levels of Dnai2 contrib-
uting to the outer dynein arm of cilia as well as of the cilia
marker b-tubulin IV were gradually enhanced. Mutants of
Dnai2 may account for primary ciliary dyskinesia (Loges
et al., 2008) supporting the critical role of this axonemal
protein for cilia motility.
On the other hand, exposure of the differentiated air-
liquid interface cultures to CSE resulted in a time-dependent
loss in Foxj1 transcripts that was paralleled by reduced Dnai2
and followed by compromised cilia motility and cells exhib-
iting the cilia marker b-tubulin IV. Previous work demon-
strates an enhanced degree of axonemal ultrastructural
abnormalities in smokers and ex-smokers compared with
non-smokers (Verra et al., 1995), and CSE was shown to
impede the development of ciliated cells (ciliogenesis) in
air-liquid interface-cultured mouse nasal epithelial cells
(Tamashiro et al., 2009). In mice exposed to tobacco smoke
for up to a year, a progressive reduction in ciliated airway
Figure 10
Roflumilast N-oxide reverses the CSE-induced loss in Foxj1 and Dnai2 of ciliated human bronchial epithelial cells. Differentiated human bronchial
epithelial cells (D-BECs) were pre-incubated with roflumilast N-oxide at 2 nM or 1 mM, or vehicle for 30 min before being exposed to CSE at 10%
for 3 days. Culture medium with fresh CSE and roflumilast N-oxide was replaced every 24 h. Then, the levels of Foxj1 (A) and Dnai2 (B) mRNA
transcripts (upper panels) and protein (lower panels) were determined by quantitative real-time RT-PCR or densitometric evaluation of Western
blots, respectively. A representative Western blot illustrating the corresponding incubations is depicted as well. Results are expressed relative to
control levels (= 1 for mRNA, = 100% for densitometric protein analyses) and shown as the means  SEM of cultures from two donors and three
experiments per donor. *P < 0.05 versus control, #P < 0.05 versus CSE.
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epithelial cells over time is observed (Simet et al., 2010). In
the current study, roflumilast N-oxide (2 nM, corresponding
to therapeutic plasma levels unbound to plasma proteins, and
1 mM) concentration-dependently reversed the CSE-induced
loss in Foxj1, Dnai2 and ciliated cells in the air-liquid inter-
face cultures. What might have caused these effects of the
PDE4 inhibitor to protect the ciliated cell phenotype from
being jeopardized by CSE? In mice, chronic smoke exposure
results in increased IL-13 in the airway epithelium associated
with deciliated areas (Bartalesi et al., 2005). It was further
disclosed that exposure of rats to tobacco smoke over 2–3
months enhances whole lung IL-13 (Cooper et al., 2010).
Strikingly, IL-13 transcripts and protein are augmented in
lungs of patients afflicted with COPD (Kim et al., 2008) or in
the bronchial submucosa of patients with chronic bronchitis
(Miotto et al., 2003). In the current study, it was observed that
exposure of the differentiated bronchial epithelial cells to CSE
up-regulated the expression of IL-13 transcripts and protein,
and this effect was gradually decreased by roflumilast
N-oxide. Complementing these findings, neutralization of
endogenously formed IL-13 using mAb-IL-13 partially pre-
vented the reduced expression of ciliated cell markers (Foxj1,
Dnai2, b-tubulin IV) secondary to CSE. On the other hand,
there is firm evidence that IL-13 reduces Foxj1 in differenti-
ated human bronchial epithelial cells associated with a loss in
ciliated cells (Laoukili et al., 2001; Gomperts et al., 2007; Tha-
vagnanam et al., 2011; Turner et al., 2011). Collectively, these
observations suggest that roflumilast N-oxide may have pre-
vented CSE-induced ciliated cell loss and the associated
reduction in Foxj1 and Dnai2 by curbing the increased IL-13
release. That PDE4 inhibitors may reduce IL-13 has been
demonstrated before. In vivo, roflumilast attenuates the
increase in lung and BAL IL-13 following bleomycin in mice
that presumably was driven by oxidative stress (Cortijo et al.,
2009). In vitro, PDE4 inhibitors such as rolipram decrease the
release of IL-13 from human T-cells (Essayan et al., 1997) and
basophils (Eskandari et al., 2004).
Finally, one limitation of the current study is that the fate
of the ciliated cells undergoing CSE-induced cilia loss has not
yet been explored. In the reported experiments, differentiated
bronchial epithelial cells exposed to CSE adopted a flattened
and elongated phenotype with fragmented cilia. Shortening
and shedding of cilia was earlier observed following exposure
of mouse nasal epithelial cells to CSE in vitro (Tamashiro et al.,
2009). While ciliated cells are usually considered as termi-
nally differentiated (Rawlins et al., 2007), in at least one
report it was shown that there may be exceptions, as IL-13
triggers transdifferentiation of ciliated cells into Goblet cells
(Turner et al., 2011). This finding may be of interest in the
context of the current study given the proposed role of IL-13
in the CSE-induced cilia loss and Foxj1 down-regulation. In
any case, the technique employed by Turner & colleagues,
that is Cre recombinase-mediated in vitro ciliated cell lineage
tagging, may be instrumental in future studies addressing the
fate of air-liquid interface-cultured human bronchial epithe-
lial cell subpopulations following their exposure to tobacco
smoke extract in the presence or absence of current or future
therapeutic agents.
Taken together, the current in vitro study showed that a
PDE4 inhibitor, roflumilast N-oxide, was able to partly
protect differentiated human bronchial epithelial cells from a
reduction in CBF and loss of ciliated cells following exposure
to tobacco smoke extract. More studies are required to deter-
mine whether these findings may translate in vivo or in
patients with COPD.
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